Kaye Scholer Represents BioTime in Acquisition of Stem Cell Assets from Geron Corporation

Kaye Scholer is representing BioTime, Inc., a developer and marketer of products in the fields of stem cells and regenerative medicine, in its acquisition, through its subsidiary BioTime Acquisition Corporation, of stem cell assets from Geron Corporation, a biotechnology company. This acquisition will enable BioTime to develop cell therapy technologies to realize the potential of regenerative medicine. The Kaye Scholer team included Partners Diane Frankle and Mark Kingsley and Associate Joseph Berkowitz.